Middle East and Asia Injectable Drugs Market, by Product Type (Pre-filled Syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-thrombolytic, Muscle R
Description
Middle East and Asia Injectable Drugs Market, by Product Type (Pre-filled Syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), by Route of Administration (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), and Others (Epidural and Intrathecal)), and by End Users (Hospitals, Clinics, and Ambulatory Surgery Centers) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness regarding drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Middle East and Asia injectable drugs market.
Middle East and Asia injectable drugs market is estimated to be valued at US$ 4,15,000 Mn in 2021 and is expected to increase to US$ 7,23,164 Mn by 2028, witnessing a CAGR of 8.2% during the forecast period.
Market Dynamics
Increase in technology advancement, increasing government initiatives in healthcare sector of Middle East, innovations and ongoing R&Ds on injectable drug delivery systems and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Asia injectable drugs market.
As per the article Bevan Brittan, 2021, The Middle East is seeing a boom in healthcare sector. Aging populations, lengthening life expectations, and different lifestyle are the factors driving the market growth. The opportunities are leading to new models of care and out of hospital facilities because of the focus on prevention and not just simple treatment. Encompassing the primary, community and secondary care, the Saudi Arabia has embarked to build a new healthcare system.
Key features of the study:
This report provides in-depth analysis of the Middle East and Asia injectable drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Asia injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Middle East and Asia injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia injectable drugs market
Detailed Segmentation:
Middle East and Asia Injectable Drugs Market, By Product Type:
Pre-filled Syringes
Vaccines
Blood Stimulants
Biologics
Others
Auto-injectors
Pre-filled Pens
Pre-mixed IV Bags
Sedative Products (Sedation)
Anesthesia Products (Anesthesia)
Pain Management Products (Post-operative analgesic pain management)
Chemotherapy Products (Chemotherapy)
Antibacterial Products (Infectious diseases)
Electrolyte and Nutrition Products (Electrolyte and Nutrition)
Others
Middle East and Asia Injectable Drugs Market, By Route of Administration:
Intramuscular (IM)
Intravenous (IV)
Subcutaneous (SC)
Others (Epidural and Intrathecal)
Middle East and Asia Injectable Drugs Market, By Drug Class:
Anesthesia
Antibiotics
Antidotes
Antiemetic
Anti-infective
Anti-thrombolytic
Muscle Relaxant
Non Opioids
Opioids
Sedatives
Others
Middle East and Asia Injectable Drugs Market, By End Users:
Hospitals
Clinics
Ambulatory Surgery Centers
Company Profiles
Kalbe Farma*
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
Takeda pharmaceuticals Co. Ltd.
Livzon Pharmaceutical Group, Inc.
Sun Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Sanofi
Novartis
Tabuk
Novo Nordisk
GlaxoSmithKline plc
AstraZeneca
Gerresheimer AG
“*” marked represents similar segmentation in other categories in the respective section.
Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness regarding drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Middle East and Asia injectable drugs market.
Middle East and Asia injectable drugs market is estimated to be valued at US$ 4,15,000 Mn in 2021 and is expected to increase to US$ 7,23,164 Mn by 2028, witnessing a CAGR of 8.2% during the forecast period.
Market Dynamics
Increase in technology advancement, increasing government initiatives in healthcare sector of Middle East, innovations and ongoing R&Ds on injectable drug delivery systems and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Asia injectable drugs market.
As per the article Bevan Brittan, 2021, The Middle East is seeing a boom in healthcare sector. Aging populations, lengthening life expectations, and different lifestyle are the factors driving the market growth. The opportunities are leading to new models of care and out of hospital facilities because of the focus on prevention and not just simple treatment. Encompassing the primary, community and secondary care, the Saudi Arabia has embarked to build a new healthcare system.
Key features of the study:
This report provides in-depth analysis of the Middle East and Asia injectable drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Asia injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Middle East and Asia injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia injectable drugs market
Detailed Segmentation:
Middle East and Asia Injectable Drugs Market, By Product Type:
Pre-filled Syringes
Vaccines
Blood Stimulants
Biologics
Others
Auto-injectors
Pre-filled Pens
Pre-mixed IV Bags
Sedative Products (Sedation)
Anesthesia Products (Anesthesia)
Pain Management Products (Post-operative analgesic pain management)
Chemotherapy Products (Chemotherapy)
Antibacterial Products (Infectious diseases)
Electrolyte and Nutrition Products (Electrolyte and Nutrition)
Others
Middle East and Asia Injectable Drugs Market, By Route of Administration:
Intramuscular (IM)
Intravenous (IV)
Subcutaneous (SC)
Others (Epidural and Intrathecal)
Middle East and Asia Injectable Drugs Market, By Drug Class:
Anesthesia
Antibiotics
Antidotes
Antiemetic
Anti-infective
Anti-thrombolytic
Muscle Relaxant
Non Opioids
Opioids
Sedatives
Others
Middle East and Asia Injectable Drugs Market, By End Users:
Hospitals
Clinics
Ambulatory Surgery Centers
Company Profiles
Kalbe Farma*
Company highlights
Product Portfolio
Key Highlights
Financial performance
Strategies
Takeda pharmaceuticals Co. Ltd.
Livzon Pharmaceutical Group, Inc.
Sun Pharmaceutical Industries, Ltd.
Pfizer, Inc.
Sanofi
Novartis
Tabuk
Novo Nordisk
GlaxoSmithKline plc
AstraZeneca
Gerresheimer AG
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
90 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By End Users
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Product approval and launches
- Merges and Acquisitions
- Key development
- Middle East and Asia drug approval process
- Regulatory Scenario
- Reimbursement Scenario
- Brand Analysis
- PEST Analysis
- Pricing Analysis
- Technology Advancement
- 4. Middle East and Asia Injectable Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- 5. Middle East and Asia Injectable Drugs Market, By Product Type, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Pre-filled Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Vaccines
- Blood Stimulants
- Biologics
- Others
- Auto-injectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Pre-filled Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Pre-mixed IV Bags
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Sedative Products (Sedation)
- Anesthesia Products (Anesthesia)
- Pain Management Products (Post-operative analgesic pain management)
- Chemotherapy Products (Chemotherapy)
- Antibacterial Products (Infectious diseases)
- Electrolyte and Nutrition Products (Electrolyte and Nutrition)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Middle East and Asia Injectable Drugs Market, By Route of Administration, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Intramuscular (IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others (Epidural and Intrathecal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 7. Middle East and Asia Injectable Drugs Market, By Drug Class , 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Antidotes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Antiemetic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Anti-infective
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Anti-thrombolytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Muscle Relaxant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Non Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Sedatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 8. Middle East and Asia Injectable Drugs Market, By End Users, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Ambulatory Surgery Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 9. Middle East and Asia Injectable Drugs Market, By Country, 2017 - 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Country Trends
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End Users, 2017 - 2028, (US$ Mn)
- Asia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End-Users, 2017 - 2028, (US$ Mn)
- 10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Kalbe Farma
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Pfizer Inc.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Novo Nordisk A/S
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Takeda Pharmaceutical Co. Ltd.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Livzon Pharmaceutical Group, Inc.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Sun Pharmaceutical Industries, Ltd.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Sanofi
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Novartis
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Tabuk
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- GlaxoSmithKline plc
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- AstraZeneca
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Gerresheimer AG
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- 11. Section
- References
- Research Methodology
- About Us and Sales Contact
- *Browse 30 market data tables and 35 figures on "Middle East and Asia Injectable Drugs Market” - forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
